BIO REFERENCE LABORATORIES INC 4
4 · BIO REFERENCE LABORATORIES INC · Filed Oct 21, 2009
Insider Transaction Report
Form 4
DUBINETT HOWARD
DirectorExecutive VP, COO
Transactions
- Sale
Common Stock
2009-10-19$29.98/sh−85,803$2,572,374→ 225,069 total
Footnotes (2)
- [F1]In lieu of an outright sale, on October 15, 2007, Howard Dubinett entered into a pre-paid variable price forward sales contract ("Forward Contract") with UBS Securities LLC ("UBS"). Pursuant to the Forward Contract, Mr. Dubinett pledged 89,047 shares of his BRLI Common Stock to secure his obligation to deliver a maximum 89,047 shares of BRLI Common Stock to UBS on October 19, 2009 (the "Settlement Date"). As prepayment for the pledge of the 89,047 shares, UBS paid Mr. Dubinett $2,572,474 or approximately $28.89 per share representing 87.9% of the proceeds from the sale of 89,047 shares of BRLI Common Stock on or about October 16, 2007. The number of shares that Mr. Dubinett was obligated to deliver on the Settlement Date varied based upon the average closing price of the Common Stock on the NASDAQ Global Market System on the four trading days ending on and including the Settlement Date. (Continued - Footnote 2).
- [F2]Mr. Dubinett was entitled to benefit from any excess of such average closing price for BRLI Common Stock between $28.89 per share up to a maximum $39.44 per share by being able to deliver fewer shares. Based on the average closing price on the four trading days, Mr. Dubinett was entitled to the return of 3,244 of the 89,047 pledged shares. The net effect of the transaction to Mr. Dubinett is that he sold 85,803 shares at a price of $29.98 per share.